Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance rituximab plus cytokine-induced killer cells in elderly high-risk DLBCL after first R-CHOP
KCT0005708Phase 2Completed
- Sponsor
- Celltrion Pharm
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, unmodified CIK in diffuse large B-cell lymphoma (DLBCL), sponsored by Celltrion Pharm. Started May 2021; status: completed.
02
Drugs
rituximabunmodified CIK
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0005708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005708.